Calmare Therapeutics Incorporated

Calmare Therapeutics Incorporated, based in Shelton, Connecticut, manufactures and supplies FDA-cleared transcutaneous electrical nerve stimulation (TENS) medical devices to federal healthcare agencies as a prime contractor across the Department of Veterans Affairs, the Department of Defense, and the National Institutes of Health. The company operates full and open, with no set-aside designations across its recent award footprint.

Calmare's product portfolio centers on non-invasive pain therapy devices, including the Calmare PMT-1, MC-5A (a 5-channel TENS stimulator), and Scrambler Therapy models. These devices deliver electrical stimulation based on stored treatment programs to support non-opioid pain management in veterans' healthcare and military medicine settings. The company holds a GSA Schedule 65-II-A (Medical Equipment and Supplies) contract, awarded July 15, 2025, with a $250,000 ceiling running through July 14, 2030. Recent delivery orders under the schedule include a $56,603 firm fixed-price order from Veterans Integrated Service Network 1 (May 8, 2026, for delivery to White River Junction, Vermont) and earlier purchase orders from Veterans Integrated Service Networks 2 and 21 for Calmare pain therapy devices and accessories, each in the $56,000 to $57,000 range (September 2022 through August 2023). The company also holds an Indefinite Delivery Contract with an unnamed federal customer.

Customer concentration is split across the VA and DoD medical commands. The top five customers by potential value account for 89% of combined dollars, led by Veterans Integrated Service Network 12 (3 awards, $2.9 million), followed by the Navy Bureau of Medicine and Surgery ($617 thousand), the Army Medical Command ($216 thousand), Veterans Integrated Service Network 1 ($164 thousand), and the Defense Health Agency ($113 thousand). By award count, the National Institutes of Health appears as the largest customer (4 awards), suggesting smaller per-award magnitudes in that relationship. The company operates exclusively as a prime contractor (100% of awards) with no documented subcontractor relationships.

Activity has remained sparse and episodic: one award per year in 2021 and 2022, three in 2023, one in 2025, and one in 2026. Combined potential value across all awards since 1995 totals $4.5 million, with $2.8 million obligated (63% realization). The NAICS and PSC coding reflects the company's core focus: Electromedical and Electrotherapeutic Apparatus Manufacturing dominates at 20 of 29 awards, with Medical and Surgical Instruments and Equipment PSC codes appearing on 19 awards.